Using predefined cutoffs, repeated CSF analyses in the same laboratory led to a change in biomarker classification (normal vs. abnormal) of 26% of subjects based on Aβ1-42, 10% based on t-tau, 29% based on p-tau, and 16% based on the AD profile (Table 2). This evidence concerns the gene MAPT and Alzheimer disease.